{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:38:11Z","timestamp":1794433091519,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004399","name":"UCB Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jaad.2023.04.063","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T11:23:22Z","timestamp":1683890602000},"page":"486-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Vanvoorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Nunez","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.04.063_bib1","first-page":"217","article-title":"Interleukin-17 cytokines: effectors and targets in a psoriasis-A breakthrough in understanding and treatment","author":"Prinz","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2023.04.063_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontol 2000"},{"key":"10.1016\/j.jaad.2023.04.063_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.04.063_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.04.063_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2023.04.063_bib6","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1038\/s41598-017-08360-9","article-title":"The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties","volume":"7","author":"Goepfert","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2023.04.063_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2023.04.063_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A\/F nanobody, in moderate-to-severe psoriasis","volume":"81","author":"Svecova","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.04.063_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.04.063_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.04.063_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.04.063_bib13","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/09546634.2018.1506081","article-title":"No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis","volume":"30","author":"Bokor-Billmann","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.04.063_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","article-title":"Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study","volume":"311","author":"Gasslitter","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2023.04.063_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/09546634.2020.1716932","article-title":"Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker \u2013 a retrospective multicenter study","volume":"32","author":"Kromer","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.04.063_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaad.2020.07.085","article-title":"Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis","volume":"84","author":"Loft","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2340\/00015555-3200","article-title":"IL-17A inhibitor switching \u2013 efficacy of ixekizumab following secukinumab failure. A single-center experience","volume":"99","author":"Sherman","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.04.063_bib19","unstructured":"European Medicines Agency. Cosentyx - Summary of Product Characteristics. 2022. Accessed September 1, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"key":"10.1016\/j.jaad.2023.04.063_bib20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2023.04.063_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jaad.2023.04.063_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib28","first-page":"1551","article-title":"Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY phase 3 trials","volume":"11","author":"Warren","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.063_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaad.2023.04.063_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.063_bib33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.04.063_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.04.063_bib35","first-page":"75","article-title":"Psoriasis and alcohol","volume":"9","author":"Svanstr\u00f6m","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jaad.2023.04.063_bib36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamadermatol.2017.3225","article-title":"Alcohol-related mortality in patients with psoriasis: a population-based cohort study","volume":"153","author":"Parisi","year":"2017","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:27:13Z","timestamp":1759274833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S019096222300782X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}